Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actualSí 82.6%
Pronosticadores
6
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 15 horas
Desactualizado29 jun 25, 18:02 UTC31 dic 26, 23:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
Manifold MarketsWill Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2026?
Manifold MarketsWill Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2028?
Manifold MarketsRaniPill microneedle pill to replace injections: approved for sale by the end of 2026?
FutuurTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurOrion (a device that promises to project artificial vision into the brains of blind people) approved for sale by the end of 2027?
FutuurReglas
This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026.
- Myostatin inhibitors are being developed to treat conditions like muscular dystrophy and obesity.
- Notable candidates include Regeneron's trevogrumab and Eli Lilly's bimagrumab.
- Approval status can be verified through official regulatory agency announcements, such as those from the FDA (https://www.fda.gov/).
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de Any myostatin inhibitor FDA approved by 2027?
- Manifold Markets cotiza Yes al 83% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve Any myostatin inhibitor FDA approved by 2027?
- Está previsto que Any myostatin inhibitor FDA approved by 2027 se resuelva el 31 de diciembre de 2026.
- ¿Cómo se liquida Any myostatin inhibitor FDA approved by 2027?
- Manifold Markets liquida este mercado del siguiente modo: This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026.
